U.S. FDA Counts 62 Deaths That Could Be Tied To Chinese Heparin
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA says it has received 62 reports of deaths that could be tied to Chinese-produced heparin, more than triple the numbers announced previously. The 62 died within the past 15 months of allergic reactions or low blood pressure, symptoms involved with contaminated heparin. The FDA cautions the heparin may not be the cause of death in all cases. Baxter International recalled most of the product in February, but the drug was produced from basic supplies also shipped to other makers of the drug, such as APP Pharmaceuticals, which said its users were not among the 62 listed by the FDA. (Click here for more
You may also be interested in...
U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin
BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.